10-K 1 d10k.htm FORM 10-K Form 10-K

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-K

 

(Mark One)

(X)   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2002

 

OR

 

¨   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                              to                             .

 

Commission File Number 1-644

 


 

LOGO

(Exact name of registrant as specified in its charter)

 

DELAWARE

 

13-1815595

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

300 Park Avenue, New York, New York

 

10022

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code 212-310-2000

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of each class


 

Name of each exchange on which registered


$4.25 Preferred Stock, without par value,

 

New York Stock Exchange

cumulative dividend

   

Common Stock, $1.00 par value

 

New York Stock Exchange

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   X   No       

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [    ]

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes   X   No       

 

The aggregate market value of Colgate-Palmolive Common Stock held by non-affiliates as of June 28, 2002, (the last business day of our most recently completed second quarter) was approximately $26.8 billion.

 

There were 537,271,633 shares of Common Stock outstanding as of February 28, 2003.

 

DOCUMENTS INCORPORATED BY REFERENCE:

 

Documents


 

Form 10-K Reference


Portions of Proxy Statement for the
2003 Annual Meeting

 

Part III, Items 10 through 13

 

*   For purposes of this calculation only, Colgate-Palmolive Common Stock held by Executive Officers and Directors of the Company serving as of June 28, 2002, has been treated as owned by affiliates.


 

PART I

 

ITEM 1.    BUSINESS

 

(a)  General Development of the Business

 

Colgate-Palmolive Company (together with its subsidiaries, the “Company” or “Colgate”), which was founded in 1806 and incorporated under the laws of the State of Delaware in 1923, is a leading consumer products company whose products are marketed in over 200 countries and territories throughout the world.

 

For recent business developments, refer to the information set forth in Part II, Item 7 of this report and Note 14 to the Consolidated Financial Statements.

 

(b)  Financial Information about Industry Segments

 

Worldwide net sales and earnings by business segment and geographic region during the last three years appear under the caption “Results of Operations” in Part II, Item 7 of this report and Note 14 to the Consolidated Financial Statements.

 

(c)  Narrative Description of the Business

 

The Company manages its business in two distinct product segments: Oral, Personal, Household Surface and Fabric Care; and Pet Nutrition. Colgate is a global leader in Oral Care with the leading toothpaste brand in the U.S. and throughout many parts of the world. Colgate’s Oral Care products include toothbrushes, toothpaste, tooth whitener, mouth rinses and dental floss, and pharmaceutical products for dentists and other oral health professionals. Significant recent product launches in this segment include Colgate Simply White at-home tooth whitening gel, Colgate 2in1 toothpaste and mouthwash, Colgate Total Plus Whitening, Colgate Herbal, Colgate Triple Action and Colgate Fresh Confidence toothpastes, and the Colgate Motion battery-powered toothbrush.

 

Colgate is a leader in many segments of the Personal Care market with several products including bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants and shave products. Colgate is the market leader in liquid soaps in the U.S. and in male deodorant sticks globally. Significant recent product launches in this segment include the Softsoap and Palmolive brands of body washes and liquid hand soaps such as Softsoap Vitamins shower gel and liquid hand soap, and Palmolive Aromatherapy shower gel, bath foam and liquid hand soap. Colgate also manufactures and markets Mennen underarm antiperspirants and deodorants and men’s toiletries.

 

Colgate manufactures and markets a wide array of products for Household Surface and Fabric Care. Major products include Palmolive and Ajax dishwashing liquid and Fabuloso household cleansers. Colgate also markets other household names in cleaning and laundry products in the U.S. such as Fab and Murphy’s oil soap. In the Company’s major markets outside the U.S., Colgate is number one in fabric conditioners with leading brands Suavitel in Latin America and Soupline in Europe. Significant recent product launches in this segment include Palmolive Spring Sensations dishwashing liquid, Ajax wipes and new variants of Ajax Fête des Fleurs cleaner.

 

Sales of Oral, Personal, Household Surface and Fabric Care products accounted for 34%, 24%, 16% and 13% of total worldwide sales in 2002, respectively. Geographically, Oral Care is a significant part of the Company’s business in Asia/Africa, comprising approximately 51% of sales in that region for 2002. For more information regarding the Company’s worldwide sales by product categories, refer to Notes 1 and 14 to the Consolidated Financial Statements included herein.

 

Colgate, through its Hill’s Pet Nutrition subsidiary, is the world leader in specialty pet nutrition products for dogs and cats. Hill’s markets pet foods primarily under two trademarks: Science Diet, which is sold by

 

2


authorized pet supply retailers, breeders and veterinarians for every day nutritional needs; and Prescription Diet for dogs and cats with disease conditions. Significant recent product launches in this segment include Science Diet Canine and Feline Oral Care, Prescription Diet Canine b/d formula that reduces the effects of canine brain aging, and Prescription Diet Canine and Feline z/d for allergic animals. Hill’s sells its products in 86 countries and leads the premium pet food segment in North America, Japan and South Africa. Sales of Pet Nutrition products accounted for 13% of the Company’s total worldwide sales in 2002.

 

Research and Development

 

Strong research and development capabilities enable Colgate to support its many brands with technologically sophisticated products for consumers’ personal and household care and pet nutrition needs. Company spending related to research and development activities was $196.6 million, $184.9 million and $176.1 million during 2002, 2001 and 2000, respectively.

 

Distribution; Competition; Trademarks and Patents

 

The Company’s products are generally marketed by a direct sales force at each individual operating subsidiary or business unit. In some instances, distributors or brokers are used. No single customer accounts for as much as 10% of the Company’s sales.

 

Most raw materials are purchased from other companies and are available from several sources. Raw material commodities such as tallow and essential oils are subject to wide price variations. No single raw material represents a significant portion of the Company’s total material requirements.

 

The Company’s products are sold in a highly competitive global marketplace which is experiencing increased trade concentration. Products similar to those produced and sold by the Company are available from competitors in the U.S. and overseas. Certain of the Company’s competitors are larger and have greater resources than the Company. In addition, private label brands sold by retail trade chains are becoming a source of competition for certain product lines of the Company. Product quality, brand recognition and acceptance and marketing capability largely determine success in the Company’s business segments.

 

Trademarks are considered to be of material importance to the Company’s business. The Company follows a practice of seeking trademark protection by all available means in the United States and throughout the world where the Company’s products are sold. Principal global trademarks include Colgate, Palmolive, Kolynos, Sorriso, Mennen, Protex, Ajax, Soupline, Suavitel, Fab, Science Diet and Prescription Diet in addition to several regional trademarks. These trademarks are of significant importance to the Company and its subsidiaries within their markets. The Company’s rights in these trademarks endure for as long as they are used and registered. Although the Company actively develops and maintains a number of patents, no single patent is considered significant to the business as a whole.

 

Employees

 

At year-end, the Company employed 37,700 employees of which 83% were located outside the United States.

 

Environmental Matters

 

It is the Company’s policy to fully comply with environmental rules and regulations. Capital expenditures for environmental control facilities totaled $27.5 million for 2002. For future years, expenditures are expected to be in the same range. The Company has programs that are designed to ensure that its operations and facilities meet or exceed applicable rules and regulations. For information regarding other environmental matters refer to Note 13 to the Consolidated Financial Statements included herein.

 

3


 

(d)  Financial Information about Foreign and Domestic Operations and Export Sales

 

For information concerning geographic area financial data refer to the information set forth under the caption “Results of Operations” in Part II, Item 7 of this report and in Note 14 to the Consolidated Financial Statements.

 

(e)  Available Information

 

The Company’s Internet address is www.colgate.com. The information contained on the Company’s website is not included as a part of, or incorporated by reference into, this Annual Report on Form 10-K. The Company makes available, free of charge, on its Internet website, its annual report on Form 10-K, its quarterly reports on Form 10-Q, its current reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934 as soon as reasonably practicable after the Company has electronically filed such material with, or furnished it to, the United States Securities and Exchange Commission.

 

ITEM 2.    PROPERTIES

 

The Company owns and leases a total of 275 properties which include manufacturing, distribution, research and office facilities worldwide. Corporate headquarters is located in leased property at 300 Park Avenue, New York, New York.

 

In the U.S., the Company operates 29 properties, of which 11 are owned. Major U.S. manufacturing and warehousing facilities used by the Oral, Personal, Household Surface and Fabric Care segment are located in Kansas City, Kansas; Morristown, New Jersey; Jeffersonville, Indiana; and Cambridge, Ohio. The Pet Nutrition segment has major facilities in Bowling Green, Kentucky; Topeka, Kansas; Commerce, California; and Richmond, Indiana. The primary research center for Oral, Personal, Household Surface and Fabric Care products is located in Piscataway, New Jersey and the primary research center for Pet Nutrition products is located in Topeka, Kansas. Other research facilities are located in select overseas locations.

 

Overseas, the Company operates 246 properties, of which 88 are owned, in over 70 countries. Major overseas facilities used by the Oral, Personal, Household Surface and Fabric Care segment are located in Australia, Brazil, Canada, China, Colombia, France, Italy, Malaysia, Mexico, South Africa, Thailand, the United Kingdom, Venezuela and elsewhere throughout the world. In some areas outside the U.S., products are either manufactured by independent contractors under Company specifications or are imported from the U.S. or elsewhere.

 

All facilities operated by the Company are, in general, well maintained and adequate for the purpose for which they are intended. The Company conducts continuing reviews of its facilities with the view to modernization and cost reduction.

 

ITEM 3.    LEGAL PROCEEDINGS

 

In 1995, the Company acquired the Kolynos oral care business from Wyeth (formerly American Home Products) (the “Seller”), as described in the Company’s Form 8-K dated January 10, 1995. On September 8, 1998, the Company’s Brazilian subsidiary received notice of an administrative proceeding from the Central Bank of Brazil primarily taking issue with certain foreign exchange filings made with the Central Bank in connection with the financing of this strategic transaction, but in no way challenging or seeking to unwind the acquisition. The Central Bank of Brazil in January 2001 notified the Company of its decision in this administrative proceeding to impose a fine, which, at the current exchange rate, approximates $75 million. The Company has appealed the decision to the Brazilian Monetary System Appeals Council (the “Council”), thereby suspending the fine pending the decision of the Council. If the fine is affirmed, interest and penalties may also be assessed. Further appeals are available within the Brazilian federal courts. Management believes, based on the opinion of

 

4


its Brazilian legal counsel and other experts, that the filings challenged by the Central Bank fully complied with Brazilian law and that the Company will prevail on appeal. The Company intends to challenge this fine vigorously. In addition, Brazilian prosecutors are reviewing the foregoing transactions as part of an overall examination of all international transfers of Reais through non-resident current accounts during the 1992 to 1998 time frame. The Company understands that this examination involves hundreds and possibly thousands of other individuals and companies. In 2002 the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda., the Brazilian subsidiary of the Seller, and the Company, as represented by its Brazilian subsidiary, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller’s subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company’s Brazilian subsidiary jointly and severally liable for any tax due from the Seller’s subsidiary. Management believes, based on the opinion of its Brazilian legal counsel, that the Company will ultimately prevail in this action. The Company intends to challenge this action vigorously.

 

In addition, the Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company’s Brazilian subsidiary in connection with the financing of the Kolynos acquisition, imposing a tax assessment which has been determined, at the current exchange rate, to approximate $30 million. The Company has filed an administrative appeal with the Brazilian internal revenue authority, and further appeals are available within the Brazilian federal courts. Management believes, based on the opinion of its Brazilian legal counsel and other experts, that the disallowance is without merit and that the Company will prevail on appeal. The Company intends to challenge this assessment vigorously.

 

For information regarding other legal matters refer to Note 13 to the Consolidated Financial Statements.

 

5


 

ITEM 4.    SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

 

None.

 

EXECUTIVE OFFICERS OF THE REGISTRANT

 

The following is a list of executive officers as of March 21, 2003:

 

Name


  

Age


  

Date First Elected Officer


  

Present Title


Reuben Mark

  

64

  

1974

  

Chairman of the Board and Chief Executive Officer

William S. Shanahan

  

62

  

1983

  

President

Lois D. Juliber

  

54

  

1991

  

Chief Operating Officer

Javier G. Teruel

  

52

  

1996

  

Executive Vice President

Ian M. Cook

  

50

  

1996

  

Executive Vice President

Stephen C. Patrick

  

53

  

1990

  

Chief Financial Officer

Andrew D. Hendry

  

55

  

1991

  

Senior Vice President

General Counsel and Secretary

Michael J. Tangney

  

58

  

1993

  

Executive Vice President

President, Colgate-Latin America

Robert J. Joy

  

56

  

1996

  

Senior Vice President

Global Human Resources

Dennis J. Hickey

  

54

  

1998

  

Vice President and

Corporate Controller

Robert C. Wheeler

  

61

  

1991

  

Chief Executive Officer

Hill’s Pet Nutrition, Inc.

Steven R. Belasco

  

56

  

1991

  

Vice President

Taxation and Real Estate

Ronald T. Martin

  

54

  

2001

  

Vice President

Global Business Practices and Public Affairs

John J. Huston

  

48

  

2002

  

Vice President

Office of the Chairman

Franck J. Moison

  

49

  

2002

  

President, Colgate-Europe

Delia H. Thompson

  

53

  

2002

  

Vice President, Investor Relations

 

Each of the executive officers listed above has served the registrant or its subsidiaries in various executive capacities for the past five years.

 

Under the Company’s By-Laws, the officers of the corporation hold office until their respective successors are chosen and qualified, or until they have resigned, retired or been removed by the affirmative vote of a majority of the Board of Directors.

 

6


 

PART II

 

ITEM 5.   MARKET FOR REGISTRANT’S COMMON STOCK AND RELATED  SHAREHOLDER MATTERS

 

Refer to the information regarding the market for the Company’s common stock and the quarterly market price information appearing under the caption “Market and Dividend Information” included on page 53 of this report; the information under “Capital Stock and Stock Compensation Plans” in Note 8 to the Consolidated Financial Statements; and the “Number of shareholders of record” and “Cash dividends declared and paid per common share” under the caption “Historical Financial Summary” included on page 54 of this report.

 

ITEM 6.   SELECTED FINANCIAL DATA

 

Refer to the information set forth under the caption “Historical Financial Summary” included on page 54 of this report.

 

ITEM 7.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

(Dollars in Millions Except Per Share Amounts)

 

The Company manufactures and markets its products in over 200 countries and territories throughout the world in two distinct business segments: Oral, Personal, Household Surface and Fabric Care; and Pet Nutrition. Segment performance is evaluated based on several factors, including operating profit. The Company uses operating profit as a measure of the basic health of the operating segments because it excludes the impact of corporate-driven decisions related to interest expense and income taxes.

 

Prior years’ segment information has been revised for new accounting requirements and certain reclassifications. Net sales were revised for the impact of the new accounting for sales incentives described in Note 2 to the Consolidated Financial Statements, with no effect on operating profit or net income. As is also described in Note 2, the Company changed its accounting for goodwill and other intangible assets in 2002. In accordance with the new standard, prior periods were not restated. Amounts for certain businesses in the Caribbean, which were previously reported in Latin America, have been reclassified to North America to conform with current year presentation and change in management responsibilities.

 

Results of Operations

 

    

2002


  

2001


  

2000


Worldwide Net Sales by Business Segment and Geographic Region

                    

Oral, Personal, Household Surface and Fabric Care

                    

North America(1)

  

$

2,374.1

  

$

2,299.9

  

$

2,216.5

Latin America

  

 

2,206.8

  

 

2,356.0

  

 

2,406.6

Europe

  

 

1,984.3

  

 

1,835.0

  

 

1,825.8

Asia/Africa

  

 

1,542.0

  

 

1,484.3

  

 

1,496.6

    

  

  

Total Oral, Personal, Household Surface and Fabric Care

  

 

8,107.2

  

 

7,975.2

  

 

7,945.5

Total Pet Nutrition(2)

  

 

1,187.1

  

 

1,109.1

  

 

1,058.9

    

  

  

Net Sales

  

$

9,294.3

  

$

9,084.3

  

$

9,004.4

    

  

  


(1)   Net sales in the U.S. for Oral, Personal, Household Surface and Fabric Care were $2,030.4, $1,976.7 and $1,896.7 in 2002, 2001 and 2000, respectively.
(2)   Net sales in the U.S. for Pet Nutrition were $714.5, $661.5 and $633.9 in 2002, 2001 and 2000, respectively.

 

7


(Dollars in Millions Except Per Share Amounts)

 

 

Net Sales

 

Worldwide net sales increased 2.5% to $9,294.3 in 2002 on volume growth of 4.5%. Net sales would have grown 5.0% excluding foreign currency translation. Net sales in the Oral, Personal, Household Surface and Fabric Care segment increased 2.0%, excluding divestitures, on 4.5% volume growth; while net sales in Pet Nutrition increased by 7.0% on 5.5% volume growth. In 2001, worldwide net sales, excluding divestitures, increased 2.0% to $9,084.3 on volume growth of 5.0%, reflecting the negative impact of foreign currency translation.

 

Gross Profit

 

Gross profit margin increased to 54.6%, above both the 2001 level of 53.4% and the 2000 level of 52.7%. This favorable trend reflects the Company’s strategy to improve all aspects of its supply chain through global sourcing, regionalization of manufacturing facilities and other cost-reduction initiatives, as well as its emphasis on higher margin products.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses as a percentage of sales were 32.6% in 2002, 32.1% in 2001 and 32.8% in 2000. The increase in 2002 was primarily driven by pension and other employee benefit costs that were partially offset by the benefit of ongoing cost-savings initiatives. In 2001, the overall spending as a percentage of sales decreased as a result of the Company’s ongoing focus on overhead reduction and the effect of translation on local currency costs. Total advertising support behind Colgate brands, including media, promotion and other consumer and trade incentives, some of which reduce reported sales, has increased by 8%, 1% and 3% in 2002, 2001 and 2000, respectively. Included in selling, general and administrative expenses is media spending of $486.6, $509.0 and $550.9 in 2002, 2001 and 2000, respectively. The trend in media spending reflects lower media pricing, the negative impact of foreign exchange and a slight shift in investment to other forms of total advertising support.

 

Other Expense, Net

 

Other expense, net, consists principally of minority interest in earnings of less-than-100%-owned consolidated subsidiaries, amortization of intangible assets, earnings from equity investments, gains and losses on interest rate and foreign currency hedge contracts that do not qualify for hedge accounting, and other miscellaneous gains and losses.

 

During 2002, other expense, net, decreased from $94.5 to $23.0 resulting from the benefit of the change in accounting for goodwill and intangible assets and changes in the fair value of foreign currency contracts. These contracts are an economic hedge of certain foreign currency debt but do not qualify for hedge accounting. During 2001, other expense, net, increased from $52.3 to $94.5 primarily due to changes in the fair value of foreign currency contracts. During 2000, the Company recorded charges of $92.7 ($61.2 aftertax) in other expense, net, including a restructuring charge related to the realignment of certain manufacturing operations and the exiting of its business in Nigeria. Also included were gains of $102.0 ($60.9 aftertax) recorded on the sale of real estate and the sale of the Viva detergent brand in Mexico.

 

Operating Profit

 

Operating profit rose 10% to $2,013.1 in 2002 from $1,834.8 in 2001, which had reflected a 5% increase from 2000 operating profit of $1,740.5. The continued increase resulted from strong volume growth and cost-saving initiatives. If prior year results were adjusted for the impact of the change in accounting for goodwill and intangible assets, operating profit would have been $1,889.1 and $1,800.2 for 2001 and 2000, respectively.

 

Interest Expense, Net

 

Interest expense, net, was $142.8 compared with $166.1 in 2001 and $173.3 in 2000. This decreasing trend is the result of lower interest rates partially offset by increased average debt levels related to share repurchases during the year.

 

8


(Dollars in Millions Except Per Share Amounts)

 

 

Income Taxes

 

The effective tax rate on income was 31.1% in 2002 versus 31.3% in 2001 and 32.1% in 2000. If 2001 and 2000 had been adjusted for the impact of the change in accounting for goodwill and intangible assets, the respective tax rates would have been 30.9% and 31.7%. Global tax planning strategies, including the realization of tax credits and incentives, reduced the effective tax rate in all three years presented.

 

Net Income

 

Net income was $1,288.3 in 2002 or $2.19 per share on a diluted basis compared with $1,146.6 in 2001 or $1.89 per share and $1,063.8 in 2000 or $1.70 per share. If results for 2001 and 2000 were adjusted for the impact of the change in accounting for goodwill and intangible assets, net income and diluted earnings per share would have been $1,190.4 and $1.96, respectively, for 2001 and $1,111.6 and $1.77, respectively, for 2000.

 

Segment Results

 

    

2002


    

2001


    

2000


 

Worldwide Operating Profit by Business Segment and
Geographic Region

                          

Oral, Personal, Household Surface and Fabric Care

                          

North America

  

$

578.7

 

  

$

516.6

 

  

$

487.9

 

Latin America

  

 

647.4

 

  

 

663.2

 

  

 

597.6

 

Europe

  

 

409.0

 

  

 

342.6

 

  

 

320.0

 

Asia/Africa

  

 

232.6

 

  

 

195.9

 

  

 

194.0

 

    


  


  


Total Oral, Personal, Household Surface and Fabric Care

  

 

1,867.7

 

  

 

1,718.3

 

  

 

1,599.5

 

Total Pet Nutrition

  

 

318.3

 

  

 

282.1

 

  

 

243.5

 

Total Corporate

  

 

(172.9

)

  

 

(165.6

)

  

 

(102.5

)

    


  


  


Operating Profit

  

$

2,013.1

 

  

$

1,834.8

 

  

$

1,740.5

 

    


  


  


 

North America

 

North America net sales grew 3.0% to $2,374.1 on volume gains of 6.0%. Volume increases were led by the strength of recently introduced products in all core categories. In the Oral Care category, innovative products such as Colgate Simply White at-home tooth whitening gel, Colgate Total Plus Whitening toothpaste, Colgate 2 in 1 toothpaste and mouthwash and the Colgate Motion battery-powered toothbrush contributed to increased volume and market share. The Personal Care category experienced incremental market share driven by volume gains from recently introduced products such as Softsoap Aromatherapy body wash and liquid hand soap, Irish Spring Vitamins deodorant bar soap and Mennen Speed Stick Power of Nature deodorant. The Household Surface Care category had increased volumes from products such as Palmolive Aromatherapy hand dishwashing liquid. In 2001, North America achieved overall sales growth of 4.0% to $2,299.9 on volume growth of 4.5%.

 

Operating profit in North America grew 12% to $578.7 as a result of volume gains, emphasis on higher margin products, and cost-savings initiatives improving gross profit margin. The impact of the discontinuation of amortization of goodwill and indefinite life intangible assets in 2002 was largely offset by increased pension and benefit costs. Operating profit in 2001 increased 6% to $516.6, reflecting volume growth and efficiencies in advertising spending.

 

9


(Dollars in Millions Except Per Share Amounts)

 

 

Latin America

 

Net sales in Latin America declined 5.5%, excluding divestitures, to $2,206.8 on 2.5% volume growth offset by the negative effect of foreign currency primarily in Venezuela, Argentina and Brazil. The strongest volume gains in the region were achieved in Mexico, Ecuador, Colombia, Venezuela and the Dominican Republic. Recently launched products including Colgate Fresh Confidence Xtreme Red Gel, Colgate Total Plus Whitening, Colgate Triple Action, Sorriso Jua + Propolis toothpastes, and Colgate Premier Ultra and Colgate Active Flexible manual toothbrushes contributed to increased volume and market share in the Oral Care category throughout the region. Other products contributing to volume gains in the region were Palmolive Naturals bar soaps, Palmolive Naturals and Caprice hair care lines, Mennen Speed Stick Power of Nature deodorant and Fabuloso Vibrante Naturaleza liquid cleaners in the Personal and Household Surface Care categories. In 2001, Latin America net sales declined 2.0% to $2,356.0 as volume gains of 5.0% were negatively impacted by foreign exchange.

 

Operating profit in Latin America decreased 2% to $647.4 as the negative effect of foreign currency offset volume growth, cost-control initiatives, and the discontinuation of amortization of goodwill and indefinite life intangible assets in 2002. Operating profit in 2001 increased 11% to $663.2 as a result of volume gains, higher gross profit margins, ongoing cost containment and efficiencies in advertising spending.

 

Europe

 

Net sales in Europe increased 8.0% to $1,984.3 on unit volume gains of 5.0% and the impact of the stronger Euro. The United Kingdom, Russia, Turkey, France and Greece achieved the strongest volume increases in the region. New products including Colgate Total Plus Whitening toothpaste and Colgate 2 in 1 toothpaste and mouthwash contributed to regional volume growth in the Oral Care category. In the Personal, Household Surface and Fabric Care categories, new products such as Palmolive Aromatherapy shower gel, foam bath and liquid hand soap, Palmolive Soft & Gentle deodorant, Soupline Lily of the Valley fabric conditioner and Ajax Wipes contributed to increased volumes and market share. In 2001, Europe net sales increased 1.0%, excluding divestitures, to $1,835.0, on volume growth of 5.5%, partially offset by the weakened Euro.

 

Operating profit in Europe increased 19% to $409.0 as a result of volume growth, gross margin improvement, the impact of the stronger Euro, and the discontinuation of amortization of goodwill and indefinite life intangible assets. Operating profit in 2001 increased 7%, excluding divestitures, to $342.6 due to volume gains and higher gross profit margins.

 

Asia/Africa

 

Net sales in Asia/Africa increased 4.0% to $1,542.0 on volume gains of 4.5% offset by the impact of foreign currencies. The Philippines, China, South Africa and Australia achieved the strongest volume gains in the region. New products including Colgate Herbal and Colgate Triple Action toothpastes, and Colgate Active Flexible and Colgate Extra Clean manual toothbrushes contributed to volume gains in the Oral Care category. In the Personal and Household Surface Care categories, recently introduced products such as Protex Herbal antibacterial bar soap and talc, Palmolive Naturals shampoo and Ajax Fêtes des Fleurs liquid cleaner helped to drive volume growth in the region. In 2001, net sales in Asia/Africa declined 1.0% to $1,484.3 as volume gains of 6.0% were offset by foreign currency weakness.

 

Operating profit grew 19% in Asia/Africa to $232.6 in 2002 and 1% to $195.9 in 2001, driven by volume gains and higher gross profit margins benefiting from regionalization of manufacturing facilities.

 

Pet Nutrition

 

Net sales for Hill’s Pet Nutrition increased 7.0% to $1,187.1 on 5.5% volume growth. North American sales increased due to the introduction of innovative new products including Science Diet Nature’s Best, a line of

 

10


(Dollars in Millions Except Per Share Amounts)

 

natural cat and dog food. Hill’s also experienced strong volume growth in Europe, South Pacific and Asia driven by new products such as Prescription Diet Canine b/d, a clinically proven product that reduces the signs of canine brain aging. In 2001, net sales for the Pet Nutrition segment increased 4.5% to $1,109.1 on 5.5% volume gains.

 

Operating profit in Pet Nutrition grew 13% to $318.3 in 2002 and 16% to $282.1 in 2001 as a result of strong volume gains and higher gross profit margins, as well as ongoing cost-savings initiatives.

 

Liquidity and Capital Resources

 

Net cash provided by operations increased 7% to $1,611.2 compared with $1,503.9 in 2001 and $1,536.2 in 2000. The increase reflects the Company’s improved profitability and working capital management partially offset by higher cash taxes, a portion of which related to a deferral of 2001 taxes into 2002 under a government relief program as a result of the events of September 11, 2001. The decrease in 2001 reflected voluntary contributions to employee benefit plans and higher cash taxes. Cash taxes in 2000 were reduced by certain tax credits that have been fully utilized. Cash generated from operations was used to fund capital spending, pay increased dividends and repurchase common shares. Voluntary contributions to benefit plans made in 2001 were reclassified in the Consolidated Statements of Cash Flows from investing activities to operating activities consistent with current year presentation.

 

Capital expenditures were 4% of net sales for 2002, 2001 and 2000. Capital spending continues to be focused primarily on projects that yield high aftertax returns. Capital expenditures for 2003 are expected to continue at the current rate of approximately 4% of net sales.

 

In 2000, other investing activities included acquisitions with an aggregate purchase price of $64.9. There were no significant acquisitions in 2002 or 2001. Certain detergent product lines in Central America were sold in 2001 and the Mexico Viva detergent brand was sold in 2000. The aggregate sale price of all 2001 and 2000 sales of brands was $12.5 and $102.5, respectively. There were no significant divestitures in 2002.

 

During 2002, long-term debt increased to $3,509.3 from $3,137.5 and total debt increased to $3,603.9 from $3,239.1, primarily due to continued share repurchases and the impact of translating debt denominated in Euros. The Company’s long-term debt rating was upgraded in 2001 to AA- by Standard & Poor’s and Aa3 by Moody’s.

 

Domestic and foreign commercial paper outstanding was $391.4 and $605.8, as of December 31, 2002 and 2001, respectively. These borrowings carry a Standard & Poor’s rating of A1+ and a Moody’s rating of P1. The commercial paper and certain current maturities of notes payable are classified as long-term debt at December 31, 2002, as the Company has the intent and ability to refinance such obligations on a long-term basis.

 

Certain of the Company’s financing arrangements require the maintenance of a minimum ratio of operating cash flow to debt. The ESOP notes guaranteed by the Company and certain amounts payable to banks contain cross-default provisions. Noncompliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements and believes the likelihood of noncompliance is remote.

 

In 1993, the Company formed a financing subsidiary with outside equity investors that purchases some of the Company’s receivables. The Company consolidates this entity, including such receivables, and reports the amounts invested by outside investors as a minority interest. The purpose of this arrangement is to provide the Company access to low-cost sources of capital. During 2000, this subsidiary ceased operations resulting in a cash payment of $113.9 to the outside investors. In 2001, the subsidiary resumed operations with funding of $89.7 from outside investors.

 

The Company repurchases common shares in the open-market and in private transactions for employee benefit plans and to maintain its targeted capital structure. Aggregate repurchases for 2002 were 20.0 million

 

11


(Dollars in Millions Except Per Share Amounts)

 

shares, with a total purchase price of $1,082.9. In 2001 and 2000, 21.7 million and 19.1 million shares were repurchased, respectively, with total purchase prices of $1,230.2 and $1,040.6, respectively.

 

Dividend payments were $413.4, up from $396.7 in 2001 and $382.4 in 2000. Common stock dividend payments increased to $.72 per share in 2002 from $.68 per share in 2001 and $.63 per share in 2000. The Series B Preference Stock dividend payments were increased to $5.76 per share in 2002 from $5.40 per share in 2001 and $5.04 in 2000. The Company recently increased the annualized common stock dividend to $.96 per share and the annualized Series B Preference Stock dividend to $7.68 per share effective in the second quarter of 2003.

 

Internally generated cash flows are adequate to support currently planned business operations and capital expenditures. Free cash flow (defined as cash generated by the business after capital expenditures and dividend payments but before acquisitions, divestitures and share repurchases) was $854.1, $767.0 and $787.2 in 2002, 2001 and 2000, respectively, and provides the Company with flexibility for further investments and/or financing. The Company has additional sources of liquidity available in the form of lines of credit maintained with various banks and access to financial markets worldwide.

 

At December 31, 2002, the Company had access to unused lines of credit of $2,082.6 and also had $586.8 available under medium-term notes.

 

The following represents the scheduled maturities of the Company’s long-term contractual obligations as of December 31, 2002.

 


        

Payments Due by Period


   

Total


  

2003


    

2004


  

2005


  

2006


  

2007


  

Thereafter


Long-term debt including current portion

 

$

3,459.1

  

$

1,109.1

(1)

  

$

308.2

  

$

400.4

  

$

266.3

  

$

247.7

  

$

1,127.4

Capitalized leases

 

 

50.2

  

 

4.9

 

  

 

5.1

  

 

5.4

  

 

5.6

  

 

5.8

  

 

23.4

Operating leases

 

 

387.6

  

 

72.3

 

  

 

62.7

  

 

55.8

  

 

49.7

  

 

48.8

  

 

98.3

Unconditional purchase
obligations

 

 

108.2

  

 

71.5

 

  

 

35.5

  

 

1.2

  

 

—  

  

 

—  

  

 

—  

   

  


  

  

  

  

  

Total

 

$

4,005.1

  

$

1,257.8

 

  

$

411.5

  

$

462.8

  

$

321.6

  

$

302.3

  

$

1,249.1

   

  


  

  

  

  

  



(1)   Long-term debt due in 2003 includes $815.5 of commercial paper and certain current maturities of notes payable that have been classified as long-term debt as of December 31, 2002, as the Company has the intent and ability to refinance such obligations on a long-term basis under its unused lines of credit which expire in 2007.

 

The Company does not have off-balance sheet financing or unconsolidated special purpose entities. The Company’s treasury and risk management policies prohibit the use of leveraged derivatives or derivatives for trading purposes. The valuations of financial instruments that are marked to market are based upon independent third-party sources including quoted market prices.

 

As more fully described in Note 13 to the Consolidated Financial Statements, the Company is party to various superfund and other environmental matters in connection with prior acquisitions. Substantially all of these liabilities have been acknowledged in writing as being covered by investment-grade insurance carriers that are presently making all their required payments directly to the cleanup efforts and are expected to do so in the future. The Company is also contingently liable with respect to lawsuits, taxes and other matters arising out of the normal course of business. It is the opinion of management that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material impact on the financial position, results of operations or ongoing cash flows of the Company.

 

12


(Dollars in Millions Except Per Share Amounts)

 

 

Restructuring Reserves

 

In December 2000, the Company recorded a charge of $63.9 ($42.5 aftertax) associated with the realignment of three manufacturing locations in Latin America and the exiting of its business in Nigeria. The charge recorded included $14.2 for termination costs and $49.7 for exiting of manufacturing operations. The restructuring was completed in 2001.

 

Managing Foreign Currency, Interest Rate and Commodity Price Exposure

 

The Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a consolidated basis by utilizing a number of techniques, including working capital management, selective borrowings in local currencies and entering into certain derivative instrument transactions in accordance with the Company’s treasury and risk management policies. The Company’s treasury and risk management policies prohibit the use of leveraged derivatives or derivatives for trading purposes.

 

With operations in over 200 countries and territories, the Company is exposed to currency fluctuation related to manufacturing and selling its products in currencies other than the U.S. Dollar. The major foreign currency exposures involve the markets in the European Union and certain Latin American countries, although all regions of the world are subject to foreign currency changes versus the U.S. Dollar. The Company actively monitors its foreign currency exposures in these markets and has been able to substantially offset the impact on earnings of foreign currency rate movements through a combination of cost-containment measures, foreign currency hedging activities and selling price increases.

 

The Company primarily utilizes currency forward and swap contracts to hedge portions of its exposures relating to foreign currency purchases and assets and liabilities created in the normal course of business. From time to time, the Company hedges certain of its forecasted foreign currency purchases using forward contracts with durations no greater than 18 months.

 

Interest rate swaps and debt issuances are utilized to manage the Company’s targeted mix of fixed and floating rate debt and to minimize significant fluctuations in earnings and cash flows that may result from interest rate volatility.

 

The Company is exposed to price volatility related to raw materials used in production. Futures and option contracts are used on a limited basis to manage volatility related to anticipated raw material inventory purchases. The results of the Company’s commodity hedging activities are not material.

 

The Company is exposed to credit loss in the event of nonperformance by counterparties to the financial instrument contracts held by the Company; however, nonperformance by these counterparties is considered remote as it is the Company’s policy to contract with diversified counterparties that have a long-term debt rating of A or higher.

 

Value at Risk

 

The Company’s risk management procedures include the monitoring of interest rate and foreign exchange exposures and hedge positions utilizing statistical analyses of cash flows, market value and sensitivity analysis. However, the use of these techniques to quantify the market risk of such instruments should not be construed as an endorsement of their accuracy or the accuracy of the related assumptions. Market exposures are evaluated using a value-at-risk (VAR) model and an earnings-at-risk (EAR) model that are intended to measure the maximum potential loss in interest rate and foreign exchange financial instruments, assuming adverse market conditions occur, given a 95% confidence level. The models utilize a variance/covariance modeling technique.

 

13


(Dollars in Millions Except Per Share Amounts)

 

Historical interest rates and foreign exchange rates from the preceding year are used to estimate the volatility and correlation of future rates.

 

The estimated maximum potential one-day loss in fair value of interest rate or foreign exchange rate instruments, calculated using the VAR model, is not material to the consolidated financial position, results of operations or cash flows of the Company in 2002 and 2001. The estimated maximum yearly loss in earnings due to interest rate or foreign exchange rate instruments, calculated utilizing the EAR model, is not material to the Company’s results of operations in 2002 and 2001. Actual results in the future may differ materially from these projected results due to actual developments in the global financial markets.

 

For information regarding the Company’s accounting policies for financial instruments and a description of financial instrument activities, refer to Note 2 and Note 7 to the Consolidated Financial Statements.

 

Recent Accounting Pronouncements

 

On January 1, 2002, the Company adopted the Financial Accounting Standards Board’s (FASB) Emerging Issues Task Force (EITF) Issue No. 00-14, “Accounting for Certain Sales Incentives,” and Issue No. 00-25, “Vendor Income Statement Characterization of Consideration Paid to a Reseller of the Vendor’s Products,” that relate to the classification of various types of sales incentives and promotional expenses. The Consolidated Statements of Income for 2001 and 2000 have been revised to reflect the reclassification of certain sales incentives and promotional expenses from selling, general and administrative expenses to a reduction of net sales and cost of sales; however, the revisions had no impact on the Company’s financial position, net income or earnings per share. These reclassifications reduced net sales by $343.5 and $353.5 and cost of sales by $2.0 and $8.5 for the years ended December 31, 2001 and 2000, respectively, with an offsetting reduction in each period in selling, general and administrative expenses.

 

On January 1, 2002, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 142, “Goodwill and Other Intangible Assets,” which eliminates the amortization of goodwill and indefinite life intangible assets but requires annual impairment reviews. In accordance with SFAS No. 142, prior period amounts were not restated. A reconciliation of previously reported net income, basic earnings per share and diluted earnings per share for 2001 and 2000 to the amounts adjusted to exclude goodwill and indefinite life intangible assets amortization is presented in Note 2 to the Consolidated Financial Statements.

 

Refer to Note 2 to the Consolidated Financial Statements for further discussion of recent accounting pronouncements.

 

Critical Accounting Policies and Use of Estimates

 

The preparation of financial statements requires management to use judgment and make estimates. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. Actual results could ultimately differ from those estimates. The accounting policies that are most critical in the preparation of the Company’s Consolidated Financial Statements are those that are both important to the portrayal of the Company’s financial condition and results of operations and require significant or complex judgments and estimates on the part of management. The Company’s critical accounting policies have been reviewed with the Audit Committee of the Board of Directors.

 

In certain instances, accounting principles generally accepted in the United States of America allow for the selection of alternative accounting methods. The Company’s significant policies that involve the selection of alternative methods are accounting for stock options, shipping and handling costs, and inventories.

 

14


(Dollars in Millions Except Per Share Amounts)

 

 

    Two alternative methods for accounting for stock options are available, the intrinsic value method and the fair value method. The Company uses the intrinsic value method of accounting for stock options, and accordingly, no compensation expense has been recognized. Under the fair value method, the determination of the pro forma amounts involves several assumptions including option life and future volatility. If the fair value method were used, diluted earnings per share for 2002 would decrease approximately 3%. (Refer to Note 2 to the Consolidated Financial Statements.)

 

    Shipping and handling costs may be reported as either a component of cost of sales or selling, general and administrative expenses. The Company reports such costs, primarily related to warehousing and outbound freight, in the Consolidated Statements of Income as a component of selling, general and administrative expenses. If such costs were included in cost of sales, gross margin as a percent to sales would decrease from 54.6% to 47.6% in 2002 with no impact on reported earnings.

 

    The Company accounts for inventories using both the first-in, first-out (FIFO) method (80% of inventories) and the last-in, first-out (LIFO) method (20% of inventories). There would be no impact on reported earnings for 2002, 2001 and 2000 if all inventories were accounted for under the FIFO method.

 

The areas of accounting that involve significant or complex judgments and estimates are pensions and other postretirement benefits, asset impairment, tax valuation allowances, and legal and other contingencies.

 

    In pension accounting, the most significant actuarial assumptions are the discount rate and the long-term rate of return on plan assets. The discount rate for domestic plans was 6.75%, 7.25% and 7.75% as of December 31, 2002, 2001 and 2000, respectively. As required, the discount rate is based upon published year-end rates on high-quality bonds. The assumed long-term rate of return on plan assets for domestic plans was 8.0%, 9.0% and 9.25% as of December 31, 2002, 2001 and 2000, respectively. This assumption is based on historical experience and long-term expectations of asset performance. A 1% change in either the discount rate or the assumed return on plan assets would impact net income by approximately $6. A third less significant assumption is the long-term rate of compensation increase, a change in which, would partially offset the impact of a change in either of the above rates.

 

    The most judgmental assumption in accounting for other postretirement benefits is the medical cost trend rate. In 2002, the assumed rate was 9% for 2003 and declining 1% per year until reaching the ultimate assumed rate of 5% per year. The effect of a 1% increase in the assumed long-term medical cost trend rate would reduce net income by approximately $1.5.

 

    Asset impairment analysis is primarily performed for intangible assets and requires several estimates including future cash flows, growth rates and the selection of a discount rate. Since the estimated fair value of the Company’s intangible assets substantially exceeds the recorded book value, significant changes in these estimates would have to occur to result in an impairment charge.

 

    Tax valuation allowances are established to reduce tax assets, such as tax loss carryforwards, to net realizable value. Factors considered in estimating net realizable value include carryforward periods, income tax strategies and forecasted taxable income. A significant change to the Company’s valuation allowances will not materially impact reported earnings.

 

    Legal and other contingency reserves are based on management’s assessment of the risk of potential loss, which includes consultation with outside legal counsel and advisors. Such assessments are reviewed each period and revised, based on current facts and circumstances, if necessary. It is management’s opinion that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material impact on the Company’s financial position, results of operations or ongoing cash flows. (Refer to Note 13 to the Consolidated Financial Statements for further discussion of the Company’s contingencies.)

 

The Company generates revenue through the sale of well-known consumer products to trade customers under established trading terms. While the recognition of revenue and receivables requires the use of estimates, there is a short time frame (typically less than 60 days) between the shipment of product and cash receipt, thereby reducing the level of uncertainty in these estimates. (Refer to Note 2 to the Consolidated Financial Statements for further description of the Company’s significant accounting policies.)

 

15


(Dollars in Millions Except Per Share Amounts)

 

 

Outlook

 

Looking forward into 2003, the Company is well positioned for continued growth in most of its markets. However, the Company operates in a highly competitive global marketplace that is experiencing increased trade concentration. In addition, movements in foreign currency exchange rates can impact future operating results as measured in U.S. Dollars. In particular, economic uncertainty in some countries in Latin America and changes in the value of the Euro may impact the overall results of Latin America and Europe.

 

The Company expects the continued success of Colgate toothpaste, using patented and proprietary technology, to bolster worldwide Oral Care leadership and expects new products in Oral Care and other categories to add potential for further growth. Overall, subject to global economic conditions, the Company does not expect the 2003 market conditions to be materially different from those experienced in 2002 and the Company expects its positive momentum to continue.

 

Historically, the consumer products industry has been less susceptible to changes in economic growth than many other industries. Therefore, the Company constantly evaluates projects that will focus operations on opportunities for enhanced growth potential. Over the long term, Colgate’s continued focus on its consumer products business and the strength of its global brand names, its broad international presence in both developed and developing markets, and its strong capital base all position the Company to take advantage of growth opportunities and to continue to increase profitability and shareholder value.

 

Cautionary Statement on Forward-Looking Statements

 

In this report and from time to time, the Company may make statements that constitute or contain “forward-looking” information as that term is defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases. Such statements may relate, for example, to sales or volume growth, earnings growth, financial goals, cost-reduction plans and new product introductions among other matters. The Company cautions investors that any such forward-looking statements made by the Company are not guarantees of future performance and that actual results may differ materially from anticipated results or expectations expressed in the Company’s forward-looking statements. The following are some of the factors that could cause actual results to differ materially from forward-looking statements:

 

  1.   Global Economic Conditions.    The Company operates on a global basis, with approximately 70% of its net sales coming from operations outside the U.S. The Company is subject to the full range of economic risks, including those associated with international operations, such as economic recession, inflation, access to capital markets and related costs, movements in currency exchange rates and interest rates, return on pension assets, trade restrictions, tax law changes, political and legal instability, the imposition of trade restrictions and similar factors beyond the control of the Company.

 

  2.   Competition.    The Company faces vigorous competition from multinational consumer product companies throughout the world with the same or greater resources than the Company. Such competition is based on pricing of products, promotional activities, advertising, new product introductions, electronic commerce initiatives and other activities of competitors, the timing and scale of which cannot be foreseen by the Company. The Company’s ability to compete also depends on the strength of its brands, its ability to attract and retain key talent, and its ability to protect its patent, trademark and trade dress rights and to defend against related challenges brought by competitors.

 

  3.   Retail Trade.    The Company can be negatively affected by changes in the policies of its retail trade customers, such as inventory de-stocking, limitations on access to shelf space, electronic data transmission requirements and other conditions. With the growing trend towards retail trade consolidation, especially in developed markets such as the U.S. and Europe, the Company is increasingly dependent on key retailers, and these retailers have increasingly greater bargaining strength. In addition, private label brands sold by retail trade chains are becoming a source of competition for certain product lines of the Company.

 

16


(Dollars in Millions Except Per Share Amounts)

 

 

  4.   Products.    The Company’s growth depends on the successful development and introduction of new products and line extensions, which face the uncertainty of retail and consumer acceptance and reaction from competitors, as well as the continued success of existing products. In addition, the Company’s ability to create new products and line extensions and to sustain existing products is affected by its ability to develop technological innovations, to receive and maintain necessary patent and trademark protection and regulatory approvals, and to anticipate successfully consumer needs and preferences.

 

  5.   Cost Pressures.    The Company’s ability to manage its cost structure can be adversely affected by movements in raw material prices and by unanticipated delays or difficulties in achieving cost efficiencies in manufacturing and distribution. In addition, the Company’s move to global suppliers, to achieve cost reductions and simplify its business, has resulted in an increasing dependence on key suppliers. For certain materials, new suppliers may have to be qualified under industry and government standards, which can require additional investment and take some period of time.

 

  6.   Manufacturing.    As a company engaged in manufacturing on a global scale, the Company is subject to the risks inherent in such activities, including industrial accidents, environmental events, strikes and other labor disputes, loss or impairment of key manufacturing sites, product quality and safety issues, natural disasters and other external factors over which the Company has no control.

 

ITEM 7A.    QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK

 

See “Managing Foreign Currency, Interest Rate and Commodity Price Exposure” and “Value at Risk” located on page 13 of this report.

 

ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

See the “Index to Financial Statements” which is located on page 24 of this report.

 

ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING

AND FINANCIAL DISCLOSURE

 

On May 16, 2002, the Company appointed PricewaterhouseCoopers LLP as the Company’s independent public accountants. For additional information, refer to the Company’s current report on Form 8-K, filed on May 17, 2002.

 

17


(Dollars in Millions Except Per Share Amounts)

 

 

PART III

 

ITEM 10.    DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

 

Information regarding directors and executive officers of the registrant set forth in the Proxy Statement for the 2003 Annual Meeting is incorporated herein by reference, as is the text in Part I of this report under the caption “Executive Officers of the Registrant”.

 

ITEM 11.    EXECUTIVE COMPENSATION

 

The information regarding executive compensation set forth in the Proxy Statement for the 2003 Annual Meeting is incorporated herein by reference.

 

ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

  (a)   Security ownership of certain beneficial owners and management set forth in the Proxy Statement for the 2003 Annual Meeting is incorporated herein by reference.

 

  (b)   There are no arrangements known to the registrant that may at a subsequent date result in a change in control of the registrant.

 

(c)

 

Equity Compensation Plan Information

 


   

(a)

    

(b)

 

(c)

Plan category

 

Number of securities to be issued upon exercise of outstanding options, warrants and rights

(in thousands)

    

Weighted-average exercise price of outstanding options, warrants and rights

 

Number of securities
remaining available for
future issuance under equity compensation plans (excluding securities reflected in

column (a))

(in thousands)


Equity compensation plans approved by security holders

 

45,306(1)

    

$44(2)

 

15,936(3)


Equity compensation plans not approved by security holders

 

Not applicable

    

Not applicable

 

Not applicable


Total

 

45,306

    

$44

 

15,936



(1)   Consists of 43,054 options and 2,252 restricted shares outstanding under the Company’s Stock Option and Incentive Stock Plans, which are more fully described in Note 8 to the Consolidated Financial Statements.
(2)   Includes weighted average exercise price of stock options outstanding of $46 and restricted shares of $0.
(3)   Amount relates to options available for issuance under the Company’s Stock Option Plans. The amount of restricted shares available for issuance under the Incentive Stock Plan during any given calendar year is 0.25% of the Company’s common stock outstanding as of January 1st of such calendar year, plus any available restricted shares from prior years that were not granted.

 

ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

The information regarding certain relationships and related transactions set forth in the Proxy Statement for the 2003 Annual Meeting is incorporated herein by reference.

 

18


(Dollars in Millions Except Per Share Amounts)

 

 

PART IV

 

ITEM 14.    CONTROLS AND PROCEDURES

 

Within the 90-day period prior to the date of this report, the Company, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (the “Evaluation”). Based upon the Evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective in ensuring that material information relating to the Company, including its consolidated subsidiaries, is made known to them by others within those entities, particularly during the period in which this annual report was being prepared. There were no significant changes in the Company’s internal controls or in other factors that could significantly affect these controls subsequent to the date of the Evaluation.

 

ITEM 15.    EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

 

  (a)   Financial Statements and Financial Statement Schedules

 

See the “Index to Financial Statements” which is located on page 24 of this report.

 

  (b)   Exhibits.    See the exhibit index which begins on page 55 of this report.

 

  (c)   Reports on Form 8-K

 

On April 12, 2002, the Company filed a current report on Form 8-K including certain reclassified income statement information for 2001 and 2000 pursuant to new accounting requirements implemented by the Emerging Issues Task Force.

 

On May 17, 2002, the Company filed a current report on Form 8-K relating to the change in its certifying accountant.

 

On August 2, 2002, the Company filed a current report on Form 8-K attaching as exhibits sworn statements made by each of the Chairman and Chief Executive Officer and the Chief Financial Officer of the Company certifying previously filed reports pursuant to Securities and Exchange Commission Order No. 4-460.

 

19


SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

COLGATE-PALMOLIVE COMPANY

                 (Registrant)

By:

 

/S/    REUBEN MARK


   

Reuben Mark

Chairman of the Board

and Chief Executive Officer

 

Date: March 21, 2003

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 21, 2003 by the following persons on behalf of the registrant and in the capacities indicated.

 

(a)    Principal Executive Officer

     

(c)    Principal Accounting Officer

/S/    REUBEN MARK


     

/S/    DENNIS J. HICKEY


Reuben Mark

Chairman of the Board

and Chief Executive Officer

     

Dennis J. Hickey

Vice President and

Corporate Controller

 

 

(b)    Principal Financial Officer

     

(d)    Directors:

/S/    STEPHEN C. PATRICK


Stephen C. Patrick

Chief Financial Officer

     

Jill K. Conway, Ronald E. Ferguson,

Carlos M. Gutierrez, Ellen M. Hancock,

David W. Johnson, Richard J. Kogan,

Delano E. Lewis, Reuben Mark,

Howard B. Wentz, Jr.

 

 

/S/    ANDREW D. HENDRY


       

Andrew D. Hendry

as Attorney-in-Fact

 

20


CERTIFICATIONS

 

I, Reuben Mark, Chairman and Chief Executive Officer of Colgate-Palmolive Company, certify that:

 

  1.   I have reviewed this annual report on Form 10-K of Colgate-Palmolive Company;

 

  2.   Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

  3.   Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

  4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

 

  (a)   Designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

  (b)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the “Evaluation Date”); and

 

  (c)   Presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

 

  5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)   All significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

 

  (b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

 

  6.   The registrant’s other certifying officer and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

 

 

 

Date: March 21, 2003

 

/S/    REUBEN MARK


   

Reuben Mark

Chairman and Chief Executive Officer

 

21


I, Stephen C. Patrick, Chief Financial Officer of Colgate-Palmolive Company, certify that:

 

  1.   I have reviewed this annual report on Form 10-K of Colgate-Palmolive Company;

 

  2.   Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

  3.   Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

  4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

 

  (d)   Designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

  (e)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the “Evaluation Date”); and

 

  (f)   Presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

 

  5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  (c)   All significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

 

  (d)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

 

  6.   The registrant’s other certifying officer and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

 

 

Date: March 21, 2003

 

/S/    STEPHEN C. PATRICK


   

Stephen C. Patrick

Chief Financial Officer

 

22


 

 

United States

Securities and Exchange Commission

Washington, D.C. 20549

 

FORM 10-K

 

CONSOLIDATED FINANCIAL STATEMENTS

For The Year Ended December 31, 2002

 

COLGATE-PALMOLIVE COMPANY

 

NEW YORK, NEW YORK 10022

 

23


Index to Financial Statements

 

    

Page


Consolidated Financial Statements

    

Consolidated Statements of Income for the years
ended December 31, 2002, 2001 and 2000

  

25

Consolidated Balance Sheets as of December 31, 2002 and 2001

  

26

Consolidated Statements of Retained Earnings, Comprehensive Income
and Changes in Capital Accounts for the years ended
December 31, 2002, 2001 and 2000

  

27

Consolidated Statements of Cash Flows for the years
ended December 31, 2002, 2001 and 2000

  

28

Notes to Consolidated Financial Statements

  

29

Schedule II—Valuation and Qualifying Accounts for the years ended
December 31, 2002, 2001 and 2000

  

48

Reports of Independent Accountants

  

51

Selected Financial Data

    

Market and Dividend Information

  

53

Historical Financial Summary

  

54

 

All other financial statements and schedules not listed have been omitted since the required information is included in the financial statements or the notes thereto or is not applicable or required.

 

24


 

COLGATE-PALMOLIVE COMPANY

 

Consolidated Statements of Income

 

For the years ended December 31,

 

(Dollars in Millions Except Per Share Amounts)

 

    

2002


  

2001


  

2000


Net sales

  

$

9,294.3

  

$

9,084.3

  

$

9,004.4

Cost of sales

  

 

4,224.2

  

 

4,234.9

  

 

4,257.0

    

  

  

Gross profit

  

 

5,070.1

  

 

4,849.4

  

 

4,747.4

Selling, general and administrative expenses

  

 

3,034.0

  

 

2,920.1

  

 

2,954.6

Other expense, net

  

 

23.0

  

 

94.5

  

 

52.3

    

  

  

Operating profit

  

 

2,013.1

  

 

1,834.8

  

 

1,740.5

Interest expense, net

  

 

142.8

  

 

166.1

  

 

173.3

    

  

  

Income before income taxes

  

 

1,870.3

  

 

1,668.7

  

 

1,567.2

Provision for income taxes

  

 

582.0

  

 

522.1

  

 

503.4

    

  

  

Net income

  

$

1,288.3

  

$

1,146.6

  

$

1,063.8

    

  

  

Earnings per common share, basic

  

$

2.33

  

$

2.02

  

$

1.81

    

  

  

Earnings per common share, diluted

  

$

2.19

  

$

1.89

  

$

1.70

    

  

  

 

 

 

See Notes to Consolidated Financial Statements.

 

25


COLGATE-PALMOLIVE COMPANY

 

Consolidated Balance Sheets

 

As of December 31,

 

(Dollars in Millions Except Per Share Amounts)

 

    

2002


    

2001


 

Assets

                 

Current Assets

                 

Cash and cash equivalents

  

$

167.9

 

  

$

172.7

 

Receivables (less allowances of $45.9 and $45.6, respectively)

  

 

1,145.4

 

  

 

1,124.9

 

Inventories

  

 

671.7

 

  

 

677.0

 

Other current assets

  

 

243.1

 

  

 

228.8

 

    


  


Total current assets

  

 

2,228.1

 

  

 

2,203.4

 

Property, plant and equipment, net

  

 

2,491.3

 

  

 

2,513.5

 

Goodwill, net

  

 

1,182.8

 

  

 

1,284.2

 

Other intangible assets, net

  

 

608.5

 

  

 

619.8

 

Other assets

  

 

576.5

 

  

 

363.9

 

    


  


Total assets

  

$

7,087.2

 

  

$

6,984.8

 

    


  


Liabilities and Shareholders’ Equity

                 

Current Liabilities

                 

Notes and loans payable

  

$

94.6

 

  

$

101.6

 

Current portion of long-term debt

  

 

298.5

 

  

 

325.5

 

Accounts payable

  

 

728.3

 

  

 

678.1

 

Accrued income taxes

  

 

121.7

 

  

 

195.0

 

Other accruals

  

 

905.6

 

  

 

823.3

 

    


  


Total current liabilities

  

 

2,148.7

 

  

 

2,123.5

 

Long-term debt

  

 

3,210.8

 

  

 

2,812.0

 

Deferred income taxes

  

 

488.8

 

  

 

480.6

 

Other liabilities

  

 

888.6

 

  

 

722.3

 

Shareholders’ Equity

                 

Preferred stock

  

 

323.0

 

  

 

341.3

 

Common stock, $1 par value (1,000,000,000 shares authorized,
732,853,180 shares issued)

  

 

732.9

 

  

 

732.9

 

Additional paid-in capital

  

 

1,133.9

 

  

 

1,168.7

 

Retained earnings

  

 

6,518.5

 

  

 

5,643.6

 

Accumulated other comprehensive income

  

 

(1,865.6

)

  

 

(1,491.2

)

    


  


    

 

6,842.7

 

  

 

6,395.3

 

Unearned compensation

  

 

(340.1

)

  

 

(345.4

)

Treasury stock, at cost

  

 

(6,152.3

)

  

 

(5,203.5

)

    


  


Total shareholders’ equity

  

 

350.3

 

  

 

846.4

 

    


  


Total liabilities and shareholders’ equity

  

$

7,087.2

 

  

$

6,984.8

 

    


  


 

See Notes to Consolidated Financial Statements.

 

26


COLGATE-PALMOLIVE COMPANY

 

Consolidated Statements of Retained Earnings, Comprehensive Income

and Changes in Capital Accounts

 

Dollars in Millions Except Per Share Amounts

 

   

Common Shares


 

Additional Paid-in Capital


   

Treasury Shares


   

Retained Earnings


   

Accumulated Other Compre-

hensive Income


   

Compre-

hensive Income


 
   

Shares


   

Amount


   

Shares


   

Amount


       

Balance, January 1, 2000

 

578,863,046

 

 

$

732.9

 

$

1,063.2

 

 

153,999,624

 

 

$

3,056.4

 

 

$

4,212.3

 

 

$

(1,136.2

)

       

Net income

                                   

 

1,063.8

 

         

$

1,063.8

 

Other comprehensive income:

                                                         

Cumulative translation adjustment

                                           

 

(133.5

)

 

 

(133.5

)

                                                     


Total comprehensive income

                                                   

$

930.3

 

                                                     


Dividends declared:

                                                         

Series B Convertible

                                                         

Preference Stock, net of income taxes

                                   

 

(20.3

)

               

Preferred stock

                                   

 

(.4

)

               

Common stock

                                   

 

(361.7

)

               

Shares issued for stock options

 

4,796,186

 

       

 

96.7

 

 

(4,796,186

)

 

 

54.3

 

                       

Treasury stock acquired

 

(19,099,681

)

               

19,099,681

 

 

 

1,040.6

 

                       

Other

 

2,096,323

 

       

 

(15.0

)

 

(2,084,163

)

 

 

(107.9

)

                       
   

 

 


 

 


 


 


       

Balance, December 31, 2000

 

566,655,874

 

 

$

732.9

 

$

1,144.9

 

 

166,218,956

 

 

$

4,043.4

 

 

$

4,893.7

 

 

$

(1,269.7

)

       
   

 

 


 

 


 


 


       

Net income

                                   

 

1,146.6

 

         

$

1,146.6

 

Other comprehensive income:

                                                         

Cumulative translation adjustment

                                           

 

(198.5

)

 

 

(198.5

)

Other

                                           

 

(23.0

)

 

 

(23.0

)

                                                     


Total comprehensive income

                                                   

$

925.1

 

                                                     


Dividends declared:

                                                         

Series B Convertible

                                                         

Preference Stock, net of income taxes

                                   

 

(21.3

)

               

Preferred stock

                                   

 

(.4

)

               

Common stock

                                   

 

(375.0

)

               

Shares issued for stock options

 

2,705,887

 

       

 

62.4

 

 

(2,705,887

)

 

 

20.5

 

                       

Treasury stock acquired

 

(21,662,879

)

               

21,662,879

 

 

 

1,230.2

 

                       

Other

 

3,023,451

 

       

 

(38.6

)

 

(3,023,261

)

 

 

(90.6

)

                       
   

 

 


 

 


 


 


       

Balance, December 31, 2001

 

550,722,333

 

 

$

732.9

 

$

1,168.7

 

 

182,152,687

 

 

$

5,203.5

 

 

$

5,643.6

 

 

$

(1,491.2

)

       
   

 

 


 

 


 


 


       

Net income

                                   

 

1,288.3

 

         

$

1,288.3

 

Other comprehensive income:

                                                         

Cumulative translation adjustment

                                           

 

(327.1

)

 

 

(327.1

)

Other

                                           

 

(47.3

)

 

 

(47.3

)

                                                     


Total comprehensive income

                                                   

$

913.9

 

                                                     


Dividends declared:

                                                         

Series B Convertible

                                                         

Preference Stock, net of income taxes

                                   

 

(21.5

)

               

Preferred stock

                                   

 

(.4

)

               

Common stock

                                   

 

(391.5

)

               

Shares issued for stock options

 

2,218,959

 

       

 

7.0

 

 

(2,218,959

)

 

 

(45.4

)

                       

Treasury stock acquired

 

(20,036,204

)

               

20,036,204

 

 

 

1,082.9

 

                       

Other

 

3,096,696

 

       

 

(41.8

)

 

(3,096,696

)

 

 

(88.7

)

                       
   

 

 


 

 


 


 


       

Balance, December 31, 2002

 

536,001,784

 

 

$

732.9

 

$

1,133.9

 

 

196,873,236

 

 

$

6,152.3

 

 

$

6,518.5

 

 

$

(1,865.6

)

       
   

 

 


 

 


 


 


       

 

See Notes to Consolidated Financial Statements.

 

27


 

COLGATE-PALMOLIVE COMPANY

 

Consolidated Statements of Cash Flows

 

For the years ended December 31,

 

(Dollars in Millions)

 

    

2002


    

2001


    

2000


 

Operating Activities

                          

Net income

  

$

1,288.3

 

  

$

1,146.6

 

  

$

1,063.8

 

Adjustments to reconcile net income to net
cash provided by operations:

                          

Depreciation and amortization

  

 

296.5

 

  

 

336.2

 

  

 

337.8

 

Gain on sale of businesses and other investment activities

  

 

(5.2

)

  

 

(10.8

)

  

 

(125.6

)

Voluntary contributions to benefit plans

  

 

(110.0

)

  

 

(95.7

)

  

 

—  

 

Cash effects of changes in:

                          

Receivables

  

 

(18.0

)

  

 

19.4

 

  

 

(91.9

)

Inventories

  

 

(2.4

)

  

 

(18.7

)

  

 

59.0

 

Accounts payable and other accruals

  

 

137.7

 

  

 

(52.5

)

  

 

97.8

 

Deferred and accrued income taxes

  

 

5.3

 

  

 

146.4

 

  

 

197.1

 

Other non-current assets and liabilities

  

 

19.0

 

  

 

33.0

 

  

 

(1.8

)

    


  


  


Net cash provided by operations

  

 

1,611.2

 

  

 

1,503.9

 

  

 

1,536.2

 

    


  


  


Investing Activities

                          

Capital expenditures

  

 

(343.7

)

  

 

(340.2

)

  

 

(366.6

)

Payment for acquisitions, net of cash acquired

  

 

—  

 

  

 

(10.2

)

  

 

(64.9

)

Sale of non-core product lines

  

 

—  

 

  

 

12.5

 

  

 

102.5

 

Sale of marketable securities and investments

  

 

1.5

 

  

 

9.3

 

  

 

137.4

 

Other

  

 

(15.0

)

  

 

5.1

 

  

 

(17.0

)

    


  


  


Net cash used in investing activities

  

 

(357.2

)

  

 

(323.5

)

  

 

(208.6

)

    


  


  


Financing Activities

                          

Principal payments on debt

  

 

(763.5

)

  

 

(595.9

)

  

 

(739.4

)

Proceeds from issuance of debt

  

 

964.5

 

  

 

887.9

 

  

 

925.4

 

Payments from (to) outside investors

  

 

—  

 

  

 

89.7

 

  

 

(113.9

)

Dividends paid

  

 

(413.4

)

  

 

(396.7

)

  

 

(382.4

)

Purchase of common stock

  

 

(1,082.9

)

  

 

(1,230.2

)

  

 

(1,040.6

)

Other

  

 

35.3

 

  

 

34.5

 

  

 

34.9

 

    


  


  


Net cash used in financing activities

  

 

(1,260.0

)

  

 

(1,210.7

)

  

 

(1,316.0

)

    


  


  


Effect of exchange rate changes on cash and cash equivalents

  

 

1.2

 

  

 

(3.6

)

  

 

(4.6

)

    


  


  


Net (decrease) increase in cash and cash equivalents

  

 

(4.8

)

  

 

(33.9

)

  

 

7.0

 

Cash and cash equivalents at beginning of year

  

 

172.7

 

  

 

206.6

 

  

 

199.6

 

    


  


  


Cash and cash equivalents at end of year

  

$

167.9

 

  

$

172.7

 

  

$

206.6

 

    


  


  


Supplemental Cash Flow Information

                          

Income taxes paid

  

$

558.8

 

  

$

346.8

 

  

$

306.3

 

Interest paid

  

 

163.0

 

  

 

221.5

 

  

 

203.0

 

Principal payments on ESOP debt, guaranteed by the Company

  

 

17.8

 

  

 

12.9

 

  

 

8.8

 

 

See Notes to Consolidated Financial Statements.

 

28


COLGATE-PALMOLIVE COMPANY

 

Notes to Consolidated Financial Statements

 

(Dollars in Millions Except Per Share Amounts)

 

1.   Nature of Operations

 

The Company manufactures and markets a wide variety of products in the U.S. and around the world in two distinct business segments: Oral, Personal, Household Surface and Fabric Care; and Pet Nutrition. Oral, Personal, Household Surface and Fabric Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, laundry and dishwashing detergents, fabric conditioners, cleansers and cleaners, bleaches and other similar items. These products are sold primarily to wholesale and retail distributors worldwide. Pet Nutrition products include pet food products manufactured and marketed by Hill’s Pet Nutrition. The principal customers for Pet Nutrition products are veterinarians and specialty pet retailers. Principal global trademarks include Colgate, Palmolive, Kolynos, Sorriso, Mennen, Protex, Ajax, Soupline, Suavitel, Fab, Science Diet and Prescription Diet in addition to various regional trademarks.

 

The Company’s principal classes of products accounted for the following percentages of worldwide sales for the past three years:

 

    

2002


    

2001